淋巴瘤CD30免疫组织化学检测及结果判读规范

CD30阳性淋巴瘤病理专家组

doi:10.19401/j.cnki.1007-3639.2023.03.005

您当前的位置：

首页 >

文章列表页 >

淋巴瘤CD30免疫组织化学检测及结果判读规范

专家述评 | 更新时间：2025-12-31

- 淋巴瘤CD30免疫组织化学检测及结果判读规范
- The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas
- 中国癌症杂志 2023年33卷第3期页码：228-234
- 作者机构：
- 作者简介：
  
  [ "李小秋，医学博士，主任医师、教授、博士研究生导师。现任复旦大学附属肿瘤医院病理科副主任、淋巴造血病理专科负责人及淋巴瘤多学科综合诊疗组副首席专家。兼任中国国家卫生健康委能力建设和继续教育中心淋巴瘤专科建设项目专家组顾问暨病理学组组长、中国抗癌协会淋巴瘤专业委员会副主任委员、中国抗癌协会血液肿瘤专业委员会常务委员暨滤泡性淋巴瘤工作组副主任委员、中国临床肿瘤学会淋巴瘤专家委员会常务委员、中华医学会病理学分会淋巴造血系统病理学组顾问、中华医学会肿瘤学分会淋巴血液学组委员、中国老年保健协会淋巴瘤专业委员会常务委员、中国医疗保健国际交流促进会病理专业委员会常务委员、中国医药教育协会淋巴疾病专业委员会常务委员、上海市抗癌协会淋巴瘤专业委员会副主任委员、上海医药行业协会血液医学转化专业委员会常务委员。曾多次受世界卫生组织和国际癌症研究机构邀请，参与执笔《WHO造血淋巴肿瘤分类（2022年）》、《WHO头颈部肿瘤分类（2017年）》、《WHO头颈部肿瘤分类（2022年）》、《WHO消化系统肿瘤分类（2019年）》及《WHO皮肤肿瘤分类（2023年）》相关章节。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.03.005
  中图分类号： R
- 收稿：2023-01-28，
  
  修回：2023-02-28，
  
  纸质出版：2023-03-30
- 稿件说明：
移动端阅览
CD30阳性淋巴瘤病理专家组. 淋巴瘤CD30免疫组织化学检测及结果判读规范[J]. 中国癌症杂志, 2023,33(3):228-234.

Pathology Expert Group CD30-Positive Lymphoma. The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas[J]. China Oncology, 2023, 33(3): 228-234.
CD30阳性淋巴瘤病理专家组. 淋巴瘤CD30免疫组织化学检测及结果判读规范[J]. 中国癌症杂志, 2023,33(3):228-234. DOI： 10.19401/j.cnki.1007-3639.2023.03.005.

Pathology Expert Group CD30-Positive Lymphoma. The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas[J]. China Oncology, 2023, 33(3): 228-234. DOI： 10.19401/j.cnki.1007-3639.2023.03.005.

摘要

CD30可在多种淋巴瘤中表达，其中经典型霍奇金淋巴瘤（classical Hodgkin lymphoma，CHL）和间变性大细胞淋巴瘤（anaplastic large cell lymphoma，ALCL）最为常见。近年来，靶向CD30的抗体药物偶联物维布妥昔单抗已获批应用于复发/难治性CHL和ALCL患者的治疗，并取得显著疗效。然而，该靶向治疗药物能否使其他类型淋巴瘤患者获益目前尚不明确，精确评估CD30表达水平对此类淋巴瘤患者的临床试验和个体化治疗有重要的指导意义。目前，CD30检测仍主要通过免疫组织化学染色的方法，尚缺乏统一、规范的检测流程及结果判读标准。本文通过分析CD30的检测现状，联合多中心研究探索CD30免疫组织化学检测流程及结果判读方法，并结合文献和专家经验，最终达成淋巴瘤CD30免疫组织化学检测及结果判读共识，希望能有助于淋巴瘤CD30表达的规范化检测。

Abstract

CD30 can be expressed in a variety of lymphoma subtypes

among which classical Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL) are the most common ones. Recently

Brentuximab vedotin

the antibody-drug conjugate targeting CD30

has been approved in the treatment of patients with refractory and relapsed CHL and ALCL

and has achieved significant curative effect. However

whether CD30-targeted therapy could benefit patients with other types of lymphoma remains largely unknown. Accurate evaluation of the expression level of CD30 may thus have important guiding significance for the clinical trials and individualized treatment of patients with those lymphomas. To date

CD30 detection is mainly via immunohistochemical staining

however

with no unified and standardized process and interpretation method. We herein described the current status on CD30 testing

and explored the procedures of immunohistochemical detection and interpretation of the results through multicentric studies. A consensus was finally reached

which was based on the combination of our research results

literature review

experts’ experience

and internal discussion among the panel members

and might hopefully contribute to standardization of the immunohistochemical detection and interpretation of CD30 expression in lymphomas.

关键词

Keywords

references

SABATTINI E , PIZZI M , TABANELLI V , et al . CD30 expression in peripheral T-cell lymphomas [J ] . Haematologica , 2013 , 98 ( 8 ): e81 - e82 . DOI: 10.3324/haematol.2013.084913 http://doi.org/10.3324/haematol.2013.084913 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.084913 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.084913

WANG G N , ZHAO W G , LI L , et al . Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma [J ] . Oncol Lett , 2017 , 13 ( 3 ): 1211 - 1215 . DOI: 10.3892/ol.2017.5592 http://doi.org/10.3892/ol.2017.5592 https://www.spandidos-publications.com/10.3892/ol.2017.5592 https://www.spandidos-publications.com/10.3892/ol.2017.5592

HU S M , XU-MONETTE Z Y , BALASUBRAMANYAM A , et al . CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study [J ] . Blood , 2013 , 121 ( 14 ): 2715 - 2724 . DOI: 10.1182/blood-2012-10-461848 http://doi.org/10.1182/blood-2012-10-461848

FRANCISCO J A , CERVENY C G , MEYER D L , et al . cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J ] . Blood , 2003 , 102 ( 4 ): 1458 - 1465 . DOI: 10.1182/blood-2003-01-0039 http://doi.org/10.1182/blood-2003-01-0039

PRO B , ADVANI R , BRICE P , et al . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase Ⅱ study [J ] . J Clin Oncol , 2012 , 30 ( 18 ): 2190 - 2196 . DOI: 10.1200/JCO.2011.38.0402 http://doi.org/10.1200/JCO.2011.38.0402 https://ascopubs.org/doi/10.1200/JCO.2011.38.0402 https://ascopubs.org/doi/10.1200/JCO.2011.38.0402

YOUNES A , GOPAL A K , SMITH S E , et al . Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma [J ] . J Clin Oncol , 2012 , 30 ( 18 ): 2183 - 2189 .

NORDI Q C . Control N-IQ. CD30 [M ] . 2017 .

LI B , ESCHRICH S A , BERGLUND A , et al . Use of the total cancer care system to enrich screening for CD30-positive solid tumors for patient enrollment into a brentuximab vedotin clinical trial: a pilot study to evaluate feasibility [J ] . JMIR Res Protoc , 2017 , 6 ( 3 ): e45 . DOI: 10.2196/resprot.7289 http://doi.org/10.2196/resprot.7289 http://www.researchprotocols.org/2017/3/e45/ http://www.researchprotocols.org/2017/3/e45/

HIRSCH F R , VARELLA-GARCIA M , BUNN P A Jr , et al . Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis [J ] . J Clin Oncol , 2003 , 21 ( 20 ): 3798 - 3807 . DOI: 10.1200/JCO.2003.11.069 http://doi.org/10.1200/JCO.2003.11.069 https://ascopubs.org/doi/10.1200/JCO.2003.11.069 https://ascopubs.org/doi/10.1200/JCO.2003.11.069

KIM H K , MOON S M , MOON J H , et al . Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin [J ] . Blood Res , 2015 , 50 ( 4 ): 254 - 256 . DOI: 10.5045/br.2015.50.4.254 http://doi.org/10.5045/br.2015.50.4.254

PRINCE H M . CD30 As a target for the treatment of cutaneous T-cell lymphoma [J ] . J Clin Oncol , 2015 , 33 ( 32 ): 3691 - 3696 . DOI: 10.1200/JCO.2015.61.9486 http://doi.org/10.1200/JCO.2015.61.9486

XU M L , GABALI A , HSI E D , et al . Practical approaches on CD30 detection and reporting in lymphoma diagnosis [J ] . Am J Surg Pathol , 2020 , 44 ( 2 ): e1 - e14 . DOI: 10.1097/PAS.0000000000001368 http://doi.org/10.1097/PAS.0000000000001368 https://journals.lww.com/10.1097/PAS.0000000000001368 https://journals.lww.com/10.1097/PAS.0000000000001368

《淋巴瘤病理诊断规范》项目组 . 淋巴组织肿瘤病理诊断规范 [J ] . 中华病理学杂志 , 2019 , 48 ( 5 ): 346 - 349 .

The Project Team of Standardization for Diagnosis Tumor Pathology of Lymphomas . Standardization for diagnosis tumor pathology of lymphomas [J ] . Chin J Pathol , 2019 , 48 ( 5 ): 346 - 349 .

李小秋 , CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测:现状与挑战 [J ] . 中国癌症杂志 , 2022 , 32 ( 6 ): 512 - 518 . DOI: 10.19401/j.cnki.1007-3639.2022.06.005 http://doi.org/10.19401/j.cnki.1007-3639.2022.06.005

LI X Q . CD30 Positive Lymphoma Pathology Expert Group. Detection of CD30 expression in lymphomas: status and challenges [J ] . China Oncol , 2022 , 32 ( 6 ): 512 - 518 .

浏览量

3566

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

CD30在淋巴瘤中的表达及检测：现状与挑战

食管鳞状细胞癌PD-L1不同抗体免疫组织化学检测的一致性分析

MMR蛋白在515例子宫内膜样腺癌中表达及其与临床病理学特征的相关性分析

淋巴瘤自体造血干细胞移植的临床实践优化探索与未来展望

儿童青少年甲状腺髓样癌临床病理学特征及预后分析